RCSI-led study aims to train next generation of brain cancer researchers

RCSI (Royal College of Surgeons in Ireland) is leading an international team of scientists on a major research study that aims to train the next generation of brain cancer researchers. The project (“GLIOTRAIN”) has received funding of almost €3.9 million from the European Commission's Horizon 2020 Research and Innovation Framework Program.

The four-year project will focus on glioblastoma (GBM), the most frequent, aggressive and lethal of all brain tumors. GBM has a universally fatal prognosis with 85% of patients dying within two years. GLIOTRAIN will develop a European biomedical research training program to investigate this complex disease. Fifteen new PhD students will be trained across the fields of tumor biology, medical oncology, computational biology, genomics, cancer drug delivery and immunotherapy.

The project is led by Professor Annette Byrne, RCSI Department of Physiology and Medical Physics & RCSI Centre for Systems Medicine. "New treatment options for GBM patients and effective precision medicine therapies are urgently required. The overall research objective of GLIOTRAIN is to identify novel therapeutic strategies, while implementing state of the art genomics and systems medicine approaches to unravel disease resistance mechanisms. Our consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners to achieve our goals" Professor Byrne commented.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antibody-drug conjugate shows preclinical efficacy